Search Share Prices
SkinBio Therapeutics agrees collaboration with University of Manchester
Life sciences company SkinBio Therapeutics will assist the University of Manchester with its investigation into how ageing affects the skin, in return for first refusal on any intellectual property that emerges.
SkinBio's collaboration with the university follows a £600,000 grant awarded to the school by the Biotechnology & Biological Sciences Research Council to enable it to carry out research which could lead to the development of novel ways to improve the health of the skin microbiome during ageing and in turn, support new approaches to prevent age-related skin conditions and promote long-term skin health.
The AIM-quoted company will act as an industrial partner on the project and will have the first refusal on any IP generated by the project, placing the company in a strong position to develop any relevant findings with the potential to extend its current portfolio of indications in skin health, anti-infection and repair.
Dr Catherine O'Neill, chief executive of SkinBioTherapeutics, said, "Unlike the gut, virtually nothing is known about possible prebiotics for the skin. This study will provide the foundations for developing novel prebiotic treatments for aged skin. This work is very complementary to the work that we have already underway at SkinBioTherapeutics in skin care, anti-infection and repair."
As of 1100 BST, SkinBio shares had collected 8.24% to 15.60p.